We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Surgery Partners (SGRY) Moves 7.7% Higher: Will This Strength Last?
Read MoreHide Full Article
Surgery Partners (SGRY - Free Report) shares ended the last trading session 7.7% higher at $15. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.4% loss over the past four weeks.
Surgery Partners scored a strong price increase on investors’ optimism surrounding the company’s impending fourth quarter 2025 financial results. Per the Zacks Consensus Estimate, the company’s revenues are expected to increase 1.1% year over year. Earnings is pegged at 31 cents for the fourth quarter.
This surgical facilities operator is expected to post quarterly earnings of $0.31 per share in its upcoming report, which represents a year-over-year change of -29.6%. Revenues are expected to be $873.54 million, up 1.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Surgery Partners, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SGRY going forward to see if this recent jump can turn into more strength down the road.
Surgery Partners belongs to the Zacks Medical Services industry. Another stock from the same industry, Natera (NTRA - Free Report) , closed the last trading session 0.4% higher at $212.46. Over the past month, NTRA has returned -11%.
Natera's consensus EPS estimate for the upcoming report has changed -3.3% over the past month to -$0.46. Compared to the company's year-ago EPS, this represents a change of -12.2%. Natera currently boasts a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
View the Zacks #1 Rank List
Image: Bigstock
Surgery Partners (SGRY) Moves 7.7% Higher: Will This Strength Last?
Surgery Partners (SGRY - Free Report) shares ended the last trading session 7.7% higher at $15. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.4% loss over the past four weeks.
Surgery Partners scored a strong price increase on investors’ optimism surrounding the company’s impending fourth quarter 2025 financial results. Per the Zacks Consensus Estimate, the company’s revenues are expected to increase 1.1% year over year. Earnings is pegged at 31 cents for the fourth quarter.
This surgical facilities operator is expected to post quarterly earnings of $0.31 per share in its upcoming report, which represents a year-over-year change of -29.6%. Revenues are expected to be $873.54 million, up 1.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Surgery Partners, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SGRY going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Surgery Partners belongs to the Zacks Medical Services industry. Another stock from the same industry, Natera (NTRA - Free Report) , closed the last trading session 0.4% higher at $212.46. Over the past month, NTRA has returned -11%.
Natera's consensus EPS estimate for the upcoming report has changed -3.3% over the past month to -$0.46. Compared to the company's year-ago EPS, this represents a change of -12.2%. Natera currently boasts a Zacks Rank of #4 (Sell).